Small-Cap Catalysts to Watch: March 31 - April 4

Ready for the beginning of the second quarter: We've analyzed various filings and press releases to pinpoint the key catalysts and conferences scheduled for this week. Stay informed and stay ahead!

Companies participating in the 19th Annual Capital Link International Shipping Forum on March 31st:

SB – Safe Bulkers, Inc.

PANL – Pangaea Logistics Solutions Ltd.

DSX – Diana Shipping Inc.

HMR – Heidmar Maritime Holdings Corp.

Companies presenting at the AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference (April 1-5, 2025, Vienna, Austria):

ANVS – Annovis Bio, Inc. (Phase 3 PD & Phase 2/3 AD data; cognitive response in PD, APOE4 advantages in AD) (April 1)

CGTX – Cognition Therapeutics, Inc. (SHINE study findings presented by VP Mary Hamby, Ph.D.)

PMN – ProMIS Neurosciences, Inc. (Showcasing computational modeling for AD, PD, ALS therapies)

GANX – Gain Therapeutics, Inc. (Poster on Phase 1b trial of GT-02287 for Parkinson’s)

ACIU – AC Immune SA (Multiple presentations on precision medicine pipeline) (April 2)

ABOS – Acumen Pharmaceuticals, Inc. (Oral/poster presentations on pTau217 assay, AβO selectivity, sabirnetug effects) (April 1-3)

VIGL – Vigil Neuroscience, Inc. (Oral presentation of Phase 1 data)

VYGR – Voyager Therapeutics, Inc. (To present additional data from the NHP study of VY1706)

Companies participating in the H.C. Wainwright 2nd Annual AI-Based Drug Discovery & Development Conference Fireside Chat (April 2):

CGEN – Compugen Ltd.

ABSI – Absci Corporation

EVAX – Evaxion Biotech A/S

Companies attending the 11th Annual Waste & Sustainability Symposium (April 3, 2025):

LOOP – Loop Industries, Inc.

SCWO – 374Water, Inc.

TOPP – Toppoint Holdings, Inc.

Other companies with key Catalysts this week:

AREB > Launching an ad campaign on CNBC, Fox Business, and top financial sites starting March 31.

BCDA > Hosting a corporate update call on March 31 at 4:30 PM ET after presenting CardiAMP HF Trial results at ACC 2025.

LWLG > Attending the 2025 Optical Fiber Conference from March 30 – April 3 at the Moscone Center, San Francisco.

CDIO > Participating in ACC.25 (March 29-31, 2025, McCormick Place, Chicago), Cardio Diagnostics will exhibit at Booth #2033, showcasing PrecisionCHD™ and the enhanced ACI™ report for CHD diagnosis and management.

VTAK > Catheter Precision will participate in the American College of Cardiology (ACC) from March 29-31, 2025 in Chicago, IL, where it will showcase its LockeT device in a poster abstract on March 31, presenting new clinical data comparing it to manual compression. The company will also have booths at the European Heart Rhythm Association (EHRA) (March 30 – April 1, 2025, Vienna, Austria), featuring its VIVO device, and at the Society of Interventional Radiology (SIR) (March 29 – April 2, 2025, Nashville, TN), where it will showcase LockeT.

PHGE > Topline Phase 2 results for BX211 in diabetic foot osteomyelitis (DFO) expected by end of March 2025

OXBR > Jay Madhu, CEO and Chairman, will participate as a panelist at the Uncorrelated Puerto Rico Summit on April 1st at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

TRAW > Will host a virtual investor event on Monday, March 31, 2025 at 10:00 AM ET. ANRO > Annual Congress of the Schizophrenia International Research Society (SIRS): March 29-April 2, 2025.

AUTL > Abstracts were accepted at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting being held in Florence, Italy, March 30 - April 2, 2025.

TNYA > Tenaya is advancing TN-201, an AAV9-based gene therapy for treating MYBPC3-associated HCM, caused by insufficient myosin-binding protein C (MyBP-C). During the late-breaking Clinical and Investigative Horizons session on March 31, data from the first cohort of adult patients in the MyPEAK-1 Phase 1b/2 clinical trial will be presented.

ADGM > The Company will participate in the scientific program of the 2025 European Heart Rhythm Association (the "Association") Annual Meeting to be held from March 30 through April 1 in Vienna, Austria.

PBM > On January 9, 2023, Psyence and iNGENū signed a letter of intent to develop Psyence's PEX010 (25mg) psilocybin drug in a Phase IIb Study. The study, involving 87 patients, will compare psilocybin-assisted psychotherapy to psychotherapy alone, using the HAM-A scale to measure anxiety. The study, which has received ethics approval, is expected to begin patient enrollment in Q1 2025.

DYAI > Microbial Engineering III: New Generation of Cell Factory to Meet the Future Challenges and Seize New Opportunities March 30-April 3, 2025.

ALXO > New ADC Clinical Candidate: Novel EGFR-directed ADC, ALX2004, planned IND submission in March 2025.

AMIX > The abstract titled Pain Mitigation in Pancreatic Adenocarcinoma: An Interim Analysis of Neurolysis via Transvascular RF Energy-Based Ablation has been accepted for poster presentation at the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Nashville, TN, on Monday, March 31, 2025, from 12:10 PM – 1:10 PM CT.

MBOT > The Company announced the acceptance of a late-breaking abstract for the Society of Interventional Radiology (SIR) annual meeting in Nashville, TN, from March 29 - April 2, 2025. Data from the ACCESS-PVI trial, evaluating LIBERTY® in peripheral vascular interventions, will be presented for the first time at a podium presentation. Francois Cornelis, MD, PhD, FCIRSE, from Memorial Sloan Kettering Cancer Center, will present the study on Wednesday, April 2, 2025, from 11:33 AM - 11:42 AM CT at the Music City Center.

LDTC > LeddarTech will showcase its LeddarVision technology at Hannover Messe 2025, from March 31 - April 4, 2025, in Hall 17, Booth #44 A. As part of the Canadian delegation, LeddarTech will feature virtual reality demos, product presentations, and customer meetings, highlighting innovations in green, digital, and resilient technologies.

OSTX > OST-HER2 will be featured in the upcoming movie Shelter Me: The Cancer Pioneers, which explores canine comparative oncology, comparing cancer treatments in dogs and humans. The movie highlights OST-HER2, an immunotherapy for osteosarcoma that uses a HER2 bioengineered form of Listeria monocytogenes to trigger an immune response against HER2-expressing cancer cells. The film will premiere on April 3, 2025, at AMC Century City in Los Angeles.

VGZ > Frederick H. Earnest, President and CEO of Vista, will be speaking at the Mining Forum Europe 2025 conference in Zurich, Switzerland. Mr. Earnest's presentation is scheduled for Wednesday, April 2, at 1:10 pm Zurich time (5:10 a.m. MDT or 7:10 a.m. EDT). INBS > Intelligent Bio Solutions will be a gold sponsor at the 2025 NDASA Conference in Jacksonville, FL, from April 1-4. Daniel Brown, Head of Clinical Affairs, will present on April 1 at 1:00 PM about the company’s Intelligent Fingerprinting Drug Testing Solution, a portable, non-invasive method for on-site drug screening using fingerprint sweat.

CTOR / CTXR > The inventory for launch is ready, and market access efforts are progressing with the successful assignment of a permanent J-code (J9161) by the Centers for Medicare & Medicaid Services, effective April 1, 2025, as well as the inclusion of LYMPHIR in the NCCN guidelines. These critical milestones will help drive clinical adoption and reimbursement for the drug.

REI > Paul McKinney, Ring's Chairman and CEO, will join Water Tower Research for a fireside chat on April 1, 2025, at 10:00 AM CT. The discussion, led by Jeff Robertson, will cover Ring's $100-million acquisition in the Permian Basin and its impact on the company's 2025 outlook.

POCI > Will participate in a webcasted fireside chat at the Lytham Partners 2025 Industrials & Basic Materials Investor Summit, taking place virtually on Tuesday, April 1, 2025.

SYTA > Will present live at the AI & Technology Virtual Investor Conference hosted by VirtualInvestorConferences.com on April 3, 2025.

FDMT > Management will participate in a fireside chat at the RBC Capital Markets 2025 Ophthalmology Conference, held virtually on April 3-4, 2025.

CING > In-Person FDA Meeting Scheduled for April 2nd.

IPHA > Members of the executive team are scheduled to participate in the Life Sciences Van Lanschot Kempen Conference, held from April 1-3, 2025, in Amsterdam, Netherlands.

ALTS > Will exhibit at the Mandalay Bay, Las Vegas from April 2nd through the three days of the show, offering product demonstrations, solutions, and general information to over 3,000 attendees.

NXL > Nexalin invites investors to a webinar on April 3, 2025, at 4:15 p.m. ET. Hosted by RedChip Companies, the event will feature CEO Mark White, who will discuss the company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as updates on the new Gen-3 HALO™ Clarity and Virtual Clinic model. RNXT > A publication on the company's Trans-Arterial Micro-Perfusion (TAMP) therapy platform will be recognized in the JVIR Award-Winning Paper Scientific Session at the SIR 2025 Annual Meeting on April 1, 2025, from 3:00-4:30 PM CT in Nashville, TN.

SURG > SurgePays completed its integration with AT&T as of April 1, 2025, following a multi-year strategic agreement signed in November 2024. The agreement provides full access to 4G LTE and 5G wireless services across North America.

BRLT > The company will participate in the JP Morgan Retail Round Up Conference in New York, NY on April 2, 2025, where management will meet with investors throughout the day.

MITQ > The company will exhibit its cinema industry solutions at CinemaCon 2025 at Caesars Palace, Las Vegas, from April 1st to 3rd. President and COO, Francois Godfrey, and CFO, Bill Greene, will host an informal investor open house on Tuesday, April 1st.

POET > The company plans to showcase its latest technology innovations and products at the Optical Fiber Communications (OFC) Conference in San Francisco, CA, from April 1st to 3rd, 2025. POET's executive management team and engineers will meet with customers and industry analysts during the event.

BLNE > The company announces the official public launch of MagicBlocks, an AI-driven sales agent platform, on April 1, 2025. Incubated by Beeline, MagicBlocks successfully completed its Beta phase with 16 clients, exceeding expectations.

IMG > On March 19, 2025, the Company announced that its subsidiary, Zhongyan Shangyue Technology Co., Ltd., signed a Business Cooperation Intent Agreement with Shanghai Huomao Cultural Development Co., Ltd. Under the agreement, Zhongyan will acquire 51% of Huomao’s equity in exchange for 200,000 shares of CIMG’s common stock, subject to a six-month lock-up period. The acquisition is expected to be completed by April 3, 2025 (based on the parties agreement plan to consummate the Transfer within 15 calendar days from the date of the Agreement March 19, 2025).

VTGN > Will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada, from April 3 to 5, 2025. The presentations will include posters exploring the age of onset of social anxiety disorder (SAD) from participants in fasedienol clinical trials, as well as new data on the characteristics of young adults with and without SAD.

RMTI > will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion42 (DTX42), hosted by the National Association of Nephrology Technicians/Technologists. The event will take place at Planet Hollywood in Las Vegas, Nevada, from April 1-4, 2025.

SGD > On March 5, 2025, SG Devco approved a stock dividend from its treasury shares, consisting of 0.05 shares of common stock for each outstanding share. Shareholders will receive one additional share for every twenty shares held, with fractional shares settled in cash based on the opening price of the common stock on April 8, 2025. The record date for the dividend is April 7, 2025, and distribution will occur after the close of trading on April 22, 2025. Trading on a stock dividend-adjusted basis will begin at market open on April 7, 2025.

IMUX > Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.